A synthetic antibody company based in East Midlands, UK.
MIP Diagnostics Ltd was founded in 2015 as a spin out from the University of Leicester by several leading experts in the field, including Prof. Sergey Piletsky, in order to commercialise various forms of Molecularly Imprinted Polymers (MIPs), sometimes called "plastic antibodies". Their proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. Whilst MIPs are exceptionally robust polymers [plastics], nanoMIPS are sufficiently small to be essentially soluble. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 14, 2020 | Series Unknown | £5.10M | 1 | — | — | Detail |
May 8, 2018 | Series A | £1.50M | 1 | Mercia Fund Managers | — | Detail |
Jun 30, 2017 | Seed | £300K | 1 | Mercia Fund Managers | — | Detail |
Jun 5, 2015 | Seed | — | 1 | Mercia Fund Managers | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Mercia Fund Managers | — | Series Unknown |